


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of Formula I or a salt thereof,



wherein;

R₁ and R₂ are independently selected from the group consisting of: -CH₃, -CH₂CH₃, -CH₂OH, -CH₂OR', -CHO, -CO₂H, and -CO₂R';

R₃ and R₄ are independently selected from the group consisting of: H, -CH₃, -CH₂CH₃, -CH₂OH, -CH₂OR', -CHO, -CO₂H, and -CO₂R';


Q is a carbon skeleton selected from the group consisting of: -CH₂-, -CY₁Y₂-, -CH₂CH₂-, -CH=CH-, -CY₁Y₂CY₃Y₄-, -CH₂CH₂CH₂-, -CH=CHCH₂-, -CH=CHCY₁Y₂-, and -CY₁Y₂CY₃Y₄CY₅Y₆-, where Y₁[[.]] and Y₂-, Y₃-, Y₄-, Y₅-, and Y₆ are independently selected from the group consisting of: H, F, Br, Cl, I, OH, OR', and SH; or any one group of Y₁/Y₂-, Y₃/Y₄-, and Y₅/Y₆ may be =O; or Y₁/Y₂ may form an epoxide; and, at least one of Y₁[[.]] and Y₂-, Y₃-, Y₄-, Y₅-, and Y₆ when present, is not H;

X₁, X₂, X₃, and X₄ are independently selected from the group consisting of: H, R, OH, -OR, -CO₂H, -CO₂R', F, Br, Cl, I, -CN, -SO₃H, -OSO₃H, NO₂, NH₂, -NHR, and -NR₂; where R is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl

group that is unsubstituted or is substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH₂, -NHR', -NR'₂, NO₂, -CO₂H, -CO₂R', and epoxide;

and R' is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH₂, -NHR'', -NR''₂, NO₂ and -CO₂H where R'' is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group[[:]]

~~providing that the compound does not have the precise structure of pelorol or any one of the group of structures consisting of:~~




2. (Currently Amended) The compound of claim 1, wherein Y₁ and Y₂.[[-Y₆]] are independently selected from H, F, Br, Cl and I.

- 3-5. (Canceled)
6. (Previously Presented) The compound of claim 1, wherein R_1 is methyl, ethyl, $-CH_2OH$, or $-CH_2OR'$.
7. (Previously Presented) The compound of claim 1, wherein R_2 is methyl, ethyl, $-CH_2OH$, or $-CH_2OR'$.
8. (Previously Presented) The compound of claim 1, wherein R' in R_1 is limited to methyl, ethyl, propyl or butyl.
9. (Previously Presented) The compound of claim 1, wherein R' in R_2 is limited to methyl, ethyl, propyl or butyl.
10. (Previously Presented) The compound of claim 8, wherein R' is limited to methyl or ethyl.
11. (Currently Amended) The compound of claim 1, wherein X_1 is H, OH, R, OR, $-CONH_2$, $-CONHR'$, or $-COR[[L_2]]$.
12. (Currently Amended) The compound of claim 1, wherein X_2 is H, OH, R, OR, $-CONH_2$, $-CONHR'$, or $-COR[[L_2]]$.
13. (Currently Amended) The compound of claim 1, wherein X_3 is H, OH, R, OR, $-CONH_2$, $-CONHR'$, or $-COR[[L_2]]$.
14. (Previously Presented) The compound of claim 1, wherein R and R' in one or more of X_1 , X_2 , and X_3 are limited to methyl, ethyl, propyl and butyl.

15. (Previously Presented) The compound of claim 1, wherein X_1 is H, OH, or $-OCH_3$.
16. (Previously Presented) The compound of claim 1, wherein X_2 is H, OH, or OCH_3 .
17. (Previously Presented) The compound of claim 1, wherein X_2 is H, OCH_3 , or $-NHOCH_3$.
18. (Previously Presented) The compound of claim 1, wherein X_3 is H, OH, or OCH_3 .
19. (Previously Presented) The compound of claim 1, wherein X_4 is H, R, OH, OR, CO_2H or CO_2R' .
20. (Previously Presented) The compound of claim 1, wherein R and R' in X_4 are limited to methyl, ethyl, propyl or butyl.
21. (Previously Presented) The compound claim 1, wherein X_4 is H, R, OH, OCH_3 , $-CO_2H$ or $-CO_2CH_3$.
22. (Canceled)
23. (Previously Presented) The compound of claim 1, having the configuration S, R, R, S at C-5, C-8, C-9 and C-10 respectively.
24. (Previously Presented) The compound of claim 1, having the configuration R, S, S, R at C-5, C-8, C-9 and C-10 respectively.

25-33. (Canceled)

34. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Formula I or pharmaceutically acceptable salts thereof,



I

wherein;

R₁ and R₂ are independently selected from the group consisting of: -CH₃, -CH₂CH₃, -CH₂OH, -CH₂OR', -CHO, -CO₂H, and -CO₂R';

R₃ and R₄ are independently selected from the group consisting of: H, -CH₃, -CH₂CH₃, -CH₂OH, -CH₂OR', -CHO, -CO₂H, and -CO₂R';

Q is ~~a carbon skeleton selected from the group consisting of: -CH₂-, -CY₁Y₂-, -CH₂CH₂-, -CH=CH-, -CY₁Y₂CY₃Y₄-, -CH₂CH₂CH₂-, -CH=CHCH₂-, -CH=CHCY₁Y₂-, [[.]] and -CY₁Y₂CY₃Y₄CY₅Y₆-~~; where Y₁[[.]] and Y₂-Y₃-Y₄-Y₅- and Y₆ are independently selected from the group consisting of: H, F, Br, Cl, I, OH, OR', and SH; or ~~any one group of~~ Y₁/Y₂-, Y₃/Y₄-, and Y₅/Y₆ may be =O; or ~~Y₁/Y₂ may form an epoxide; and, at least one of Y₁[[.]] and Y₂-Y₃-Y₄-Y₅- and Y₆ when present, is not H;~~

X₁, X₂, X₃, and X₄ are independently selected from the group consisting of: H, R, OH, -OR, -CO₂H, -CO₂R', F, Br, Cl, I, -CN, -SO₃H, -OSO₃H, NO₂, NH₂, -NHR, and -NR₂; where R is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or is substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH₂, -NHR', -NR'₂, NO₂, -CO₂H, -CO₂R', and epoxide;

and R' is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH₂, -NHR", -NR"₂, NO₂ and -CO₂H where R" is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group.

35. (Canceled)

36. (Currently Amended) The pharmaceutical composition of claim 34, further comprising pelorol.

37-38. (Canceled)